Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
REPORT DATE (DD-MM-YYYY)
30-09-2010
REPORT TYPE
Annual
DATES COVERED (From -To)
TITLE AND SUBTITLE
Oxytocin and Social Support as
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) AND ADDRESS(ES)
PERFORMING ORGANIZATION REPORT NUMBERUniversity of Delaware Newark, Delaware 19716
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research And Materiel Command Fort Detrick, Maryland
SPONSOR/MONITOR'S REPORT
21702-5012
NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for public release; distribution unlimited
SUPPLEMENTARY NOTES
ABSTRACTThe purpose of the grant is to test whether exogenous oxytocin acts as an antianxiety agent and whether social support facilitates its antianxiety effects in a fear-potentiated startle paradigm. Oxytocin given systemically (0.1 µg/kg, sc) effectively reduced background anxiety, but not specific cue-potentiated fear. This was found when oxytocin was given either before fear conditioning (acquisition), immediately after fear conditioning (consolidation), or before retrieval/expression of conditioned fear-potentiated startle. Social isolation for 3 weeks potentiated startle; this was reversed by oxytocin. Intracerebroventricular infusion of oxytocin only reduced background anxiety with a very large dose (20 µg), suggesting indirect action in brain. It is concluded that oxytocin has unique antianxiety properties that reduce background and social-isolation anxiety -anxiety states not directly related to cue-specific fear, but are sustained beyond the immediate threat. Oxytocin might be promising as a drug with novel benefits for patients with PTSD. Two additional experiments demonstrated that oxtyocin did not merely reduce the ability to startle and that oxtyocin's effect was not due to reduction of contextually conditioned fear. We concluded oxytocin has a novel antianxiety profile that targets background anxiety -an anxiety state not directly related to cue--specific or contextual fear, but sustained beyond the immediate threat. Preliminary forms of this research were also presented at two meetings. The abstracts are in Appendix...